Boehringer Ingelheim reaches more patients in 2024 and prepares new medicine launches

  • Number of patients reached in 2024 jumps 8% to 66 million
  •  R&D investments rise to EUR 6.2 billion, 23.2% of group net sales
  • Company prepares new product launches starting in 2025

Boehringer Ingelheim today announced a continued rise in the number of patients it reached, 66 million in 2024, up 8.0% from the previous year. Development of its current product pipeline is well on track, as the company prepares multiple new product launches, starting in 2025. Research & Development (R&D) investments rose to EUR 6.2 billion, or 23.2% of group net sales. Group net sales rose by 6.1%* to EUR 26.8 billion.

“As our current pipeline continues to mature and more products come closer to a potential market introduction, we have entered a pivotal phase of high investments,” said Hubertus von Baumbach, Chairman of the Board of Managing Directors. “It is important that we use every opportunity to bring these new treatments to patients as fast as possible – this is our number one priority.”

Human Pharma: investing in existing products and new launches

Human Pharma sales rose by 7.0%* to EUR 21.9 billion, led by JARDIANCE® and OFEV®. Sales of JARDIANCE®, which is now also available for treatment of chronic kidney diseases, in addition to type 2 diabetes and heart failure, rose 14.6%* to EUR 8.4 billion. OFEV®, which is used to treat idiopathic pulmonary fibrosis and certain fibrosing interstitial lung diseases, grew 8.9%* to EUR 3.8 billion. 

The Human Pharma pipeline includes over ten new Phase II and III trials over the next 12 to 18 months, which will potentially result in a range of significant launches in the next five years. Human Pharma R&D spending rose to EUR 5.7 billion, or 27.6% of the business unit’s net sales.

“If we look at the past five years, Boehringer Ingelheim has invested approximately EUR 25 billion in R&D,” said Frank Hübler, Member of the Board of Managing Directors with responsibility for Finance. “With the innovations currently in our pipeline we will further increase investments in R&D in the years to come.”

After positive data from pivotal studies, the company is preparing multiple new product launches, starting this year with potential launches of zongertinib and nerandomilast.

Nerandomilast has the potential to advance care for patients with Idiopathic Pulmonary Fibrosis (FIBRONEER™-IPF) and Progressive Pulmonary Fibrosis (FIBRONEER™-ILD).  Full data from both phase III FIBRONEER™-trials, which met their primary endpoint, will be presented in the coming months.

If approved, zongertinib would be the first orally administered, targeted therapy for previously treated HER2-mutated lung cancer patients. Zongertinib’s development was accelerated due to positive Phase 1b Beamion LUNG-1 trial data, which showed a response rate of 71% (95% CI, 60–80), p<0.0001**, and disease control rate of 93%. It was generally well tolerated, with a low toxicity-related discontinuation rate (3%). Additional studies in HER2-altered solid tumors are ongoing. 

Both zongertinib and nerandomilast have been submitted to regulatory authorities globally and first launches in the US are anticipated in the second half of this year, pending approval.

Animal Health: rapid response against transboundary animal diseases

Animal Health sales rose 1.9%* to EUR 4.7 billion in 2024, mainly driven by Pet Parasiticides and Therapeutics, Poultry and Ruminant. The parasiticides NEXGARD® continued to strengthen its position as the top-selling brand in the industry, growing 14.0%* to EUR 1.4 billion.  

Last year, Boehringer Ingelheim supported livestock producers and governments by quickly providing vaccines and technical assistance for outbreaks of transboundary animal diseases (TADs), such as avian influenza, bluetongue virus and foot-and-mouth disease.  These diseases pose a significant risk to animal health, impede global trade, and constrain food supply.

Sustainable Development

Boehringer Ingelheim is on track in its target to become carbon neutral in its company operations (Scope 1 and 2) by 2030. It increased global renewable electricity purchases to around 75% in 2024, primarily due to transitioning to renewable solutions at various sites, including Japan and China. A new biomass power plant was also commissioned at its Ingelheim site in Germany to boost on-site renewable energy generation to 95% of its energy needs. 

As part of its global effort to stop rabies, the company provided 46 million rabies vaccine doses and supported vaccination campaigns in endemic countries. The “Angels” initiative, which aims to optimize the quality of treatment in existing stroke centers, added over 1,000 organizations to the network. It is the largest stroke community in the world, now encompassing 237,000 healthcare professionals from more than 9,000 hospitals in 158 countries and has helped 19 million stroke patients to date.

Outlook

The general trends and developments of the past year are expected to continue to impact 2025. The company expects a continued rise in the number of patients reached, and a slight year-on-year increase in net sales, adjusted for currency and extraordinary effects.

* sales growth numbers are adjusted for currency effects
**one-sided p-value from a z-test of the null hypothesis ORR ≤30%

Boehringer Ingelheim

Boehringer Ingelheim is a biopharmaceutical company active in both human and animal health. As one of the industry’s top investors in research and development, the company focuses on developing innovative therapies that can improve and extend lives in areas of high unmet medical need. Independent since its foundation in 1885, Boehringer takes a long-term perspective, embedding sustainability along the entire value chain. Our approximately 54,500 employees serve over 130 markets to build a healthier and more sustainable tomorrow. Learn more at www.boehringer-ingelheim.com.   

Attachment

  • Boehringer Laboratory

Boehringer Ingelheim reaches more patients in 2024 and prepares new medicine launches


THỦ THUẬT HAY

Hướng dẫn đổi ngôn ngữ sang tiếng Việt trong Mini World: Block Art

Bạn có thể tự tạo thế giới riêng cho mình, thỏa sức sáng tạo ra những sản phẩm kiến trúc, hay luyện tập kỹ năng sinh tồn ở chế độ chơi sinh tồn trong game, hoặc tham gia vào các phòng chơi với nhiều chế độ hấp dẫn. Tuy

Thay màn hình iPhone 6S ở đâu chính hãng, giá rẻ

Thay màn hình iPhone 6s ở đâu chính hãng, giá rẻ ? Bạn có thích được hưởng bảo hành mặt kính hay màn hình lâu hơn 3 đến 6 tháng ?. Bạn đã thực sự yên tâm khi đi sửa chữa điện thoại? Không chỉ tốn tiền về linh kiện, mất

Cách chèn chữ vào hình ảnh trên Word

Trên Word có tùy chọn để bạn có chèn chữ vào trong hình ảnh, để thiết kế banner, thiệp mừng, tăng tính nghệ thuật cho ảnh mà không cần dùng đến phần mềm chỉnh sửa như Photoshop.

Cách tạo Zalo Page miễn phí trên điện thoại

Để tạo Zalo Page trên điện thoại hay máy tính, chúng ta sẽ sử dụng thông qua tài khoản Zalo Official Account. Sau đó, bạn có thể đăng thông tin về Zalo Shop cũng như các mặt hàng kinh doanh.

Tải phần mềm Foxit Reader Full Crack + Hướng dẫn cài đặt [Bản mới nhất 2023]

Foxit Reader là một phần mềm đọc file PDF phổ biến, tương thích với hầu hết các hệ điều hành và cung cấp nhiều tính năng như đọc, chỉnh sửa, tạo ghi chú và chữ ký PDF. Với dung lượng nhỏ cùng với giao diện đơn giản

ĐÁNH GIÁ NHANH

Mở hộp và trải nghiệm nhanh camera Nokia 7 Plus: Rất ấn tượng

Toàn màn hình là xu hướng thiết kế của điện thoại thông minh trong năm 2017. Đại đa số các nhà sản xuất đã chuyển đổi một phần các sản phẩm chủ chốt của mình theo xu hướng này. Ở MWC 2018, HMD Global cũng không chịu

Đánh giá tổng quan Infinix Hot S: Thêm một sự lựa chọn trong tầm giá 3 triệu đồng

Infinix Hot S, nổi bật với thiết kế kim loại đẹp mắt, thời lượng sử dụng pin ấn tượng và camera tốt trong tầm giá khoảng 3 triệu đồng ở thời điểm hiện tại.

Đánh giá Kawasaki Bajaj Pulsar 200NS: Môtô giá rẻ cho giới trẻ

Mẫu môtô giá rẻ Kawasaki Bajaj Pulsar 200NS 2016 được nhập khẩu nguyên chiếc về Việt Nam nổi bật với thiết kế mạnh mẽ, tay lái rộng cùng giá bán khá mềm chỉ 78 triệu đồng.